How does Amgen make money?

AMGEN INC – Business Breakdown

The Essentials

Amgen Inc. operates as a single-segment global human therapeutics business, discovering, developing, manufacturing, and delivering medicines worldwide. The company’s industrial footprint is anchored in a broad portfolio of principal products spanning immunology, bone health, oncology, rare disease, and cardiovascular care, with commercialization supported through pharmaceutical wholesalers and direct-to-consumer channels. Its scale is substantial: FY 2025 total product sales reached $35.1 billion, with the U.S. contributing 73% and the rest of world 27%. The profile indicates a business model built on biologics, branded therapeutics, and collaboration-led expansion, rather than diversified operating segments.

Business Model & Revenue Drivers

Amgen’s economic value is generated through the commercialization of human therapeutics, with revenue concentration in a portfolio of named products and partnered programs.

• Core product sales: The company’s principal products include Enbrel, Otezla, Prolia, XGEVA, Repatha, Nplate, KYPROLIS, Aranesp, EVENITY, Vectibix, BLINCYTO, TEPEZZA, KRYSTEXXA, and others such as Neulasta, MVASI, AMJEVITA/AMGEVITA, and TEZSPIRE.
• Geographic monetization: FY 2025 product sales of $35.1 billion were predominantly U.S.-based, indicating that domestic reimbursement and market access remain the primary revenue engine.
• Collaborative commercialization: The company has strategic collaborations with AstraZeneca (TEZSPIRE), Novartis (Aimovig), UCB (EVENITY), Kyowa Kirin (rocatinlimab), and BeOne/BeiGene (oncology), suggesting that partnership structures are an important mechanism for pipeline leverage and market reach.
• Volume-led growth: The profile cites 13% global volume growth in 2025, with U.S. volume up 13% and ROW up 14%, partially offset by a 3% net price decline tied to biosimilar and competitive pressure.
• Portfolio resilience vs. erosion: Revenue generation is supported by label expansion and product lifecycle management, but the business remains exposed to patent expiry and biosimilar substitution, particularly in mature franchises.

Strategic Edge & Market Positioning

Amgen’s competitive position is best understood as a narrow structural moat, not a fortress-like franchise.

Economic Moat

• Patents and exclusivity are the clearest structural advantage. The profile explicitly identifies high-value patents as the primary moat, with developed-product rights and IPR&D carrying substantial intangible value.
• Biologic switching costs are meaningful: physician familiarity, reimbursement protocols, and patient stability create friction against rapid substitution.
• Manufacturing scale provides some cost and supply-chain leverage, supported by owned facilities and third-party manufacturing relationships.

Execution Advantage

• The company appears to execute effectively on volume growth, label expansion, and manufacturing capacity buildout.
• However, the profile also shows that execution is being used to offset structural pressure from biosimilars, generics, and patent cliffs.
• The moat is therefore real but finite-lived: patent protection and biologic complexity support pricing power today, but the erosion of exclusivity for products such as Prolia/XGEVA underscores the fragility of the long-term barrier without pipeline replacement.

Outlook & Innovation Pipeline

The next three years appear centered on pipeline conversion, lifecycle expansion, and manufacturing reinforcement.

• MariTide (maridebart cafraglutide) is the most strategically important development cited: a GLP-1/GIPR peptide-antibody conjugate with six Phase 3 studies initiated in 2025, following positive Phase 2b 52-week data in November 2024.
• Label expansion and clinical maturation are also important for TEZSPIRE, EVENITY, BLINCYTO, and Repatha, all of which reported 2025 developments.
• Oncology and immunology partnerships remain a key pipeline vector through Kyowa Kirin and BeOne/BeiGene.
• The company is also investing in R&D infrastructure, including a new Thousand Oaks R&D facility, alongside manufacturing expansion in Ohio, North Carolina, and Puerto Rico.
• From a capital allocation perspective, the profile points to continued dividend growth, share repurchases, and debt management, while management seeks to offset patent losses through new product launches, expanded indications, and direct-to-patient initiatives.

Overall, the profile portrays Amgen as a large-scale biologics platform with durable but not unassailable competitive advantages, where future value creation will depend heavily on successful pipeline execution and disciplined lifecycle management.